Business
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways ...
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation
About this update from Telomir Pharmaceuticals, Inc.
[{"type":"text","content":"Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's \n This unique cellular activity may help restore energy balance and improve essential cell functions such as protein synthesis and membrane stability in diseases like Parkinson's ALS Alzheimer's and Progeria where mitochondrial failure and oxidative stress drive progression MIAMI, FL / ACCESS Newswire / July 24, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a preclinical-stage biotechnology company developing therapies that target the root causes of biological aging and age-related diseases, today announced new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial function without triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria Syndrome (HGPS).The study was conducted in collaboration with Smart Assays Biotechnologies Ltd., a leading preclinical contract research organization specializing in advanced cell-based models and drug mechanism profiling. Researchers used a Progeria human fibroblast cell line that models the mitochondrial dysfunction, oxidative stress, and premature aging associated with this rare genetic disorder.\"This cell line-specific metabolic response may reflect selective engagement of mitochondrial pathways-an encouraging signal for therapeutic programs targeting neurodegenerative diseases where mitochondrial dysfunction drives progression,\" said Dr. Raphael Mayer, CEO of Smart Assays. \"For example, the compound's mode of action may be relevant to Parkinson's disease, where mitochondrial stress and redox imbalance directly contribute to dopaminergic neuron loss. We've worked with many companies developing mitochondrial-targeted therapies, and Telomir-1 stands out with one of the most distinctive profiles we've seen.\"A Targeted Approach to Cellular Energy RestorationMitochondria are the \"power plants\" of the cell, responsible for generating the energy needed for survival, repair, and communication. In many serious diseases-including Progeria, Werner's disease, ALS, Parkinson's, and Alzheimer's-mitochondria los...